| Patents for C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies (149,320) |
|---|
| 06/28/2005 | US6911320 Pituitary tumor transforming gene (PTTG), formerly pituitary tumor specific gene (PTTG) |
| 06/28/2005 | US6911315 Method for the detection, identification, enumeration and confirmation of virally infected cells and other epitopically defined cells in whole blood |
| 06/28/2005 | US6911309 Nucleic acids encoding MTAse |
| 06/28/2005 | US6911220 Inactivating mature recipient t cells and introducing into a primate recipient fetal or neonatal thymic tissue from a donor of a different species; restoring thymus dependent ability for progenitors to develop into mature t cells |
| 06/28/2005 | US6911208 Fungicides; diagnosis of pityrosporum infection; antiallergens |
| 06/28/2005 | US6911206 Fusion proteins comprising carriers that can induce a dual immune response |
| 06/28/2005 | US6911178 Contacting the sample containing an antibody specific for isolated and purified antigenically-active blood group antigen protein or peptide to allow the formation of an immune complex; and detecting the immune complex |
| 06/28/2005 | CA2101924C Specific peptide sequences of hepatic stage p. falciparum bearing epitopes capable of stimulating t lymphocytes |
| 06/23/2005 | WO2005057176A2 Method for identification of enzymes |
| 06/23/2005 | WO2005056825A1 Screening for modulators of mekk2 and mekk3 |
| 06/23/2005 | WO2005056807A2 Bovine adeno-associated viral (baav) vector and uses thereof |
| 06/23/2005 | WO2005056798A1 Method of reinforcing antibody activity |
| 06/23/2005 | WO2005056759A2 Methods of generating variant proteins with increased host string content and compositions thereof |
| 06/23/2005 | WO2005056606A2 Optimized antibodies that target the epidermal growth factor receptor |
| 06/23/2005 | WO2005056605A1 Modified antibodies recognizing trimer receptor or higher |
| 06/23/2005 | WO2005056604A1 ANTI-MPl ANTIBODY |
| 06/23/2005 | WO2005056603A1 Cell death inducing agent |
| 06/23/2005 | WO2005056602A1 Method of screening modified antibody having agonistic activity |
| 06/23/2005 | WO2005056601A2 Human anti-pseudomonas-aeruginosa antibodies derived from transgenic xenomouse? |
| 06/23/2005 | WO2005056600A2 Monoclonal antibodies that bind or neutralize dengue virus |
| 06/23/2005 | WO2005056599A2 Antibodies that specifically bind pms2 |
| 06/23/2005 | WO2005056594A1 Akt ACTIVITY SPECIFICALLY INHIBITING POLYPEPTIDE |
| 06/23/2005 | WO2005056585A2 Sars coronavirus s proteins and uses thereof |
| 06/23/2005 | WO2005056575A2 INTEGRIN αIIbβ3 SPECIFIC ANTIBODIES AND PEPTIDES |
| 06/23/2005 | WO2005056053A1 Use of goat serum for veterinary treatment |
| 06/23/2005 | WO2005056052A1 Neutralizing human antibodies to anthrax toxin generated by recall technology |
| 06/23/2005 | WO2005056044A1 Use of c-reactive protein to treat immune complex-mediated renal disease |
| 06/23/2005 | WO2005055936A2 Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells |
| 06/23/2005 | WO2005055810A2 Risk markers for cardiovascular disease |
| 06/23/2005 | WO2005047512A3 Plasmid system for multigene expression |
| 06/23/2005 | WO2005044856A3 Removal of high molecular weight aggregates using hydroxyapatite chromatography |
| 06/23/2005 | WO2005037999A9 Treatment of cancer using antibodies to lrrc15 |
| 06/23/2005 | WO2005037312A3 Binding molecules for the extra-domain b of fibronectin, used for the detection of atherosclerotic plaques |
| 06/23/2005 | WO2005030798A3 TNFαCONVERTING ENZYME INHIBITORY AGENTS AND STIMULATORY AGENTS- |
| 06/23/2005 | WO2005030119A3 Botulinum toxin a peptides and methods of predicting and reducing immunoresistance to botulinum toxin therapy |
| 06/23/2005 | WO2005023849A3 Antigenic peptides of rabies virus and uses thereof |
| 06/23/2005 | WO2005023083A3 Compositions and methods for the treatment of severe acute respiratory syndrome (sars) |
| 06/23/2005 | WO2005019270A3 Endotheliase-2 ligands |
| 06/23/2005 | WO2005007695A3 Anti-cd63 antibodies and methods of use thereof |
| 06/23/2005 | WO2005003298A3 Surrogate therapeutic endpoint for anti-ctla-4 based immunotherapy of disease |
| 06/23/2005 | WO2005000901A3 Cd20-specific antibodies and methods of employing same |
| 06/23/2005 | WO2004106380A3 Human-anti-human cd3 binding molecules |
| 06/23/2005 | WO2004078928A3 T cell regulation |
| 06/23/2005 | WO2004058986A3 Btl-ii nucleic acids, proteins, and antibodies |
| 06/23/2005 | WO2004035752A3 ALTERATION OF FcRn BINDING AFFINITIES OR SERUM HALF-LIVES OF ANTIBODIES BY MUTAGENESIS |
| 06/23/2005 | WO2004028564A8 Treatment of pathologies which escape the immune response, using optimised antibodies |
| 06/23/2005 | WO2004018997A3 Methods and compositions for modulating amyloid beta |
| 06/23/2005 | WO2003106639A8 Recombination of nucleic acid library members |
| 06/23/2005 | WO2003102163A8 Methods of diagnosing and treating diabetes and insulin resistance |
| 06/23/2005 | WO2003059879A3 Method of inhibiting atherosclerotic plaque destabilization |
| 06/23/2005 | US20050138692 Production of cancer-specific antibodies in plants |
| 06/23/2005 | US20050137385 IL-23p40 specific immunoglobulin derived proteins, compositions, methods and uses |
| 06/23/2005 | US20050137384 Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation |
| 06/23/2005 | US20050137131 UspA1 and UspA2 antigens of Moraxella catarrhalis |
| 06/23/2005 | US20050136515 Nucleotide sequences coding membrane protein for use in identifying modulators for prevention and treatment of cell proliferative, inflammatory, nervous system and autoimmune diseases |
| 06/23/2005 | US20050136514 Related to sodium/glucose cotransporter subfamily; drug screening; biochips; host cells |
| 06/23/2005 | US20050136511 GABA B receptors |
| 06/23/2005 | US20050136502 Treatment of disorders associated with elevated blood glucose or blood pressure |
| 06/23/2005 | US20050136494 Expression vector comprising nucleotide sequences coding immunoglobulin specific to transmembrane receptor for use in diagnosis, prevention and treatment of cell proliferative disorders; immunotherapy |
| 06/23/2005 | US20050136489 Biomarkers for liver diseases and method for using the same |
| 06/23/2005 | US20050136482 In vitro methods for determining in vivo thrombotic events |
| 06/23/2005 | US20050136476 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins and uses thereof |
| 06/23/2005 | US20050136475 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 06/23/2005 | US20050136467 Neuregulin fusion comprising epidermal growth factor domain for use in treatment and prevention of nervous system and neurodegenerative disorders |
| 06/23/2005 | US20050136434 Isolated heat-inducible cell surface protein and hyperthermia-based tumor immunotargeting therapy |
| 06/23/2005 | US20050136429 SIRT1 modulation of adipogenesis and adipose function |
| 06/23/2005 | US20050136428 Look-through mutagenesis |
| 06/23/2005 | US20050136402 Cancer antigen peptide and/or major histocompatibility complex binding sites for use as tools in detection and tretment of cell proliferative disorders; immunotherapy; genetic vaccine |
| 06/23/2005 | US20050136066 Providing autologous target diseased cell, treating to increase the levels of one or more primary and costimulatory T cell activation molecules in target diseased cell, attaching bridge molecule to diseased cell, collecting bridged cells |
| 06/23/2005 | US20050136063 Anti-IGFR antibody therapeutic combinations |
| 06/23/2005 | US20050136061 Anti-retroviral agents, compositions, methods and uses |
| 06/23/2005 | US20050136060 Antibody fragments are selected from Fab fragments, Fv fragments, single domain antigen binding fragments, scFv and aggregates thereof; for treatment of solid tumor carcinomas |
| 06/23/2005 | US20050136059 Cancer treatment methods using selected antibodies to aminophospholipids |
| 06/23/2005 | US20050136058 Insulin-like growth factor binding protein (IGFBP-5) |
| 06/23/2005 | US20050136057 Chimeric L chain comprising an L chain C region of a human antibody and an L chain V region of a mouse monoclonal antibody against a human parathyroid hormone related protein; may be used widely in hypercalcemia associated with various cancers |
| 06/23/2005 | US20050136056 Administrating as an active ingredient a substance that inhibits binding between glycoprotein Ib and von Willebrand factor as treatment of thrombocytopenia caused by hepatic failure, such as hepatic cirrhosis, viral hepatitis, drug-induced hepatitis, autoimmune hepatitis, alcoholic hepatitis |
| 06/23/2005 | US20050136055 CD40 antibody formulation and methods |
| 06/23/2005 | US20050136054 Humanised antibodies |
| 06/23/2005 | US20050136053 Tie1-binding ligands |
| 06/23/2005 | US20050136052 Method for enhancing growth or increasing feed efficiency through reducing binding between endotoxin and its receptor in the gastrointestinal tract |
| 06/23/2005 | US20050136051 Mixing a first molecule comprising IgG4 antibody heavy chain fragments capable of forming hinge region intra-heavy chain disulfide bonds with a second molecule comprising IgG4 antibody heavy chain fragments capable of forming hinge region intra-heavy chain disulfide bonds; incubating |
| 06/23/2005 | US20050136050 Bispecific antibodies |
| 06/23/2005 | US20050136049 Molecularly engineered binding domain-immunoglobulin fusion proteins, including single chain Fv-immunoglobulin fusion protein useful for treating malignant conditions and B-cell disorders, such as disease caused by autoantibody production |
| 06/23/2005 | US20050136047 Hapten-carrier conjugates for treating and preventing nicotine addiction |
| 06/23/2005 | US20050136004 Biosynthesis of biodrug by inoculating an animal with a polypeptide; producing antibodies of cytokine suppressive antiinflammatory drugs; antibody is modified with polyoxyethylene glycol; inflammatory bowel disease, ulcerative colitis, Crohn's disease, arthritis, and psoriasis |
| 06/23/2005 | US20050136001 Fluorinated carbohydrate conjugates |
| 06/23/2005 | DE10355251A1 Water-based pharmaceutical preparation for treatment of tumors has active ingredient effective against receptor of endothelial growth factor receptor |
| 06/23/2005 | DE10354403A1 Gegen das Prothrombin-Fragment F 1+2 gerichtete Antikörper, ihre Herstellung und Verwendung Against the prothrombin fragment 1 + F 2 directed antibody, their preparation and use |
| 06/23/2005 | DE10353593A1 Leptinantagonist und Verfahren zur quantitativen Messung von Leptin Leptin antagonist and method for quantitative measurement of leptin |
| 06/23/2005 | CA2832293A1 Single nucleotide polymorphisms associated with cardiovascular disorders and statin response, methods of detection and uses thereof |
| 06/23/2005 | CA2549236A1 Risk markers for cardiovascular disease |
| 06/23/2005 | CA2548950A1 Methods for enhancing antibody activity |
| 06/23/2005 | CA2548929A1 Cell death inducing agent |
| 06/23/2005 | CA2548901A1 Use of goat blood serum derived antibodies obtained after challenge with hiv lysate for veterinary treatment |
| 06/23/2005 | CA2548817A1 Methods of generating variant proteins with increased host string content and compositions thereof |
| 06/23/2005 | CA2548813A1 Antibodies that specifically bind pms2 |
| 06/23/2005 | CA2548808A1 Monoclonal antibodies that bind or neutralize dengue virus |
| 06/23/2005 | CA2548567A1 Anti-mpl antibody |
| 06/23/2005 | CA2548243A1 Integrin aiib.beta.3 specific antibodies and peptides |
| 06/23/2005 | CA2548180A1 Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells |